Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
9.03
+0.04 (0.44%)
Nov 20, 2024, 4:00 PM EST - Market closed
Daxor Revenue
Daxor had revenue of $71.76K in the half year ending June 30, 2024, a decrease of -46.94%. This brings the company's revenue in the last twelve months to $154.21K, down -13.06% year-over-year. In the year 2023, Daxor had annual revenue of $163.42K, down -29.45%.
Revenue (ttm)
$154.21K
Revenue Growth
-13.06%
P/S Ratio
283.43
Revenue / Employee
$4,168
Employees
37
Market Cap
43.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | 380.14K | -49.82K | -11.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CareCloud | 111.01M |
| Fortress Biotech | 81.50M |
| SCYNEXIS | 8.57M |
| Omega Therapeutics | 8.10M |
| Affimed | 6.29M |
| Dyadic International | 3.36M |
| Envoy Medical | 278.00K |
| Actinium Pharmaceuticals | 81.00K |
DXR News
- 6 weeks ago - DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - GlobeNewsWire
- 6 weeks ago - Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 7 weeks ago - Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device - GlobeNewsWire
- 2 months ago - Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - GlobeNewsWire
- 2 months ago - Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care - GlobeNewsWire
- 2 months ago - Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter - GlobeNewsWire
- 2 months ago - Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network - GlobeNewsWire